CAS 1622848-92-3

(S)-5-Benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-1H-1,2,4-triazole-3-carboxamide

CAS: 1622848-92-3

Formula: C₂₀H₁₉N₅O₃

Purity: 99%

Color and Shape: Solid

Molecular weight: 377.3966

Ref: IN-DA00AQYH

GSK2982772

CAS: 1622848-92-3

GSK2982772

Purity: ≥98%

Molecular weight: 377.4g/mol

Ref: 54-BUP07579

(S)-3-Benzyl-N-(5-Methyl-4-Oxo-2,3,4,5-Tetrahydrobenzo[b][1,4]Oxazepin-3-Yl)-1H-1,2,4-Triazole-5-Carboxamide

CAS: 1622848-92-3

(S)-3-Benzyl-N-(5-Methyl-4-Oxo-2,3,4,5-Tetrahydrobenzo[b][1,4]Oxazepin-3-Yl)-1H-1,2,4-Triazole-5-Carboxamide

Purity: 99%

Molecular weight: 377.4g/mol

Ref: 54-OR1023972

GSK2982772

CAS: 1622848-92-3

GSK2982772 is an inhibitor of receptor interacting serine/threonine kinase 1 (RIPK1)with IC50 values of 16 nM and 20 nM for human and monkey RIP1, respectively.

Formula: C₂₀H₁₉N₅O₃

Purity: 99.27% - 99.31%

Color and Shape: Solid

Molecular weight: 377.4

Ref: TM-T7151

(S)-5-BENZYL-N-(5-METHYL-4-OXO-2,3,4,5-TETRAHYDROBENZO[B][1,4]OXAZEPIN-3-YL)-1H-1,2,4-TRIAZOLE-3-CARBOXAMIDE

CAS: 1622848-92-3

Formula: C₂₀H₁₉N₅O₃

Purity: 99%

Molecular weight: 377.404

Ref: 10-F539520

GSK 2982772

CAS: 1622848-92-3

An ultraselective, first-in-class inhibitor of the Receptor Interacting Protein 1 (RIP1) kinase with nanomolar potency. The compound occupies allosteric pockets characteristic of type II and type III classes of kinase inhibitors. It blocks the TNF-induced necrotic cell death and reduces the production of cytokines IL-1β and IL-6 from ulcerative colitis explant tissue. Potential candidate for treatment of inflammatory diseases such as psoriasis, ulcerative colitis and rheumatoid arthritis.

Formula: C₂₀H₁₉N₅O₃

Purity: Min. 95%

Molecular weight: 377.4 g/mol

Ref: 3D-BG166667